Genmab A/S GENMAB ORD SHS/ DK0010272202 /
2024-05-23 6:35:02 PM | Chg. -12.8 | Volume | Bid2024-05-23 | Ask2024-05-23 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2,034.3DKK | -0.62% | 2,381 Turnover: 4.89 mill. |
-Bid Size: - | -Ask Size: - | 133.8 bill.DKK | - | 30.39 |
GlobeNewswire
05-21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
05-17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
05-14
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
04-07
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
03-20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
03-20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
03-11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
03-06
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
03-04
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire
02-08
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
02-08
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
01-31
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
01-22
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...